GSK, iTeos Therapeutics to co-develop and co-commercialise cancer drug
TIGIT, a part of the CD226 checkpoint axis, has shown potential as a promising target for the next generation of immuno-oncology therapies based on preclinical data and a
Vividion Therapeutics has announced plans to broaden its capabilities with the establishment of a new research and development (R&D) centre and corporate headquarters at San Diego in California, US.
Pharmaceutical company Indivior has collaborated with French biotechnology company Aelis Farma to advance the clinical development of a treatment for cannabis use disorder (CUD) and cannabis-induced psychosis (CIP).